Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;93(1):e1-e3.
doi: 10.1097/QAI.0000000000003170.

Prospective Single-Center Cohort Study on HIV Pre-exposure Prophylaxis Reveals Transient but Relevant Elevations in Transaminase Levels in Some Participants Albeit Otherwise High Tolerability

Lukas Weimann  1   2 , Guido Schäfer  1   3 , Hanna Matthews  1 , Maria Florey  4 , Robin Scheiter  1 , Anja Hüfner  1 , Sabine Jordan  1   2 , Marc Grenz  5 , Stefan Schmiedel  1   2 , Julian Schulze Zur Wiesch  2   3 , Olaf Degen  1 , Till Koch  1   2   6
Affiliations

Prospective Single-Center Cohort Study on HIV Pre-exposure Prophylaxis Reveals Transient but Relevant Elevations in Transaminase Levels in Some Participants Albeit Otherwise High Tolerability

Lukas Weimann et al. J Acquir Immune Defic Syndr. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

G.S. has received honoraria from Abbvie, Gilead, MSD, and ViiV Healthcare. J.S.z.W. has received honoraria from Gilead and was supported by the European Research Council (ERC H2020 grant 681032), the H.W. & J. Hector Stiftung (project M2101), and the Germans Center for Infection Research (DZIF TTU 04.816). O.D. has received honoraria and research funding from Gilead, Janssen, MSD, and ViiV Healthcare and participates in advisory boards for Gilead, Janssen, MSD, ViiV Healthcare, and Theratechnologies. L.W., H.M., M.F., and T.K. have declared no conflicts of interest.

References

    1. (EMA) EMA. Emtricitabin/Tenofovir disoproxil Mylan (Emtricitabin/Tenofovir disoproxil). Available at: https://www.ema.europa.eu/en/documents/overview/emtricitabine/tenofovir-... . Accessed April 19, 2022.
    1. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.
    1. Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4:e402–e410.
    1. Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19:817.
    1. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. Aids. 2019;33:1455–1465.